{"id":232832,"date":"2026-03-08T22:14:55","date_gmt":"2026-03-09T03:14:55","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/effect-of-tocilizumab-on-pro-b-type-natriuretic-peptide-and-infarct-size-in-patients-with-acute-myocardial-infarction-at-risk-of-cardiogenic-shock-dobermann-t"},"modified":"2026-03-08T22:14:55","modified_gmt":"2026-03-09T03:14:55","slug":"effect-of-tocilizumab-on-pro-b-type-natriuretic-peptide-and-infarct-size-in-patients-with-acute-myocardial-infarction-at-risk-of-cardiogenic-shock-dobermann-t","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/effect-of-tocilizumab-on-pro-b-type-natriuretic-peptide-and-infarct-size-in-patients-with-acute-myocardial-infarction-at-risk-of-cardiogenic-shock-dobermann-t","title":{"rendered":"Effect of Tocilizumab on Pro\u2013B-Type Natriuretic Peptide and Infarct Size in Patients With Acute Myocardial Infarction at Risk of Cardiogenic Shock (DOBERMANN-T)"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/effect-of-tocilizumab-on-pro-b-type-natriuretic-peptide-and-infarct-size-in-patients-with-acute-myocardial-infarction-at-risk-of-cardiogenic-shock-dobermann-t2.jpg\"><\/a><\/p>\n<p>Early IL-6 receptor inhibition with tocilizumab in AMI patients at increased risk of CS safely suppressed systemic inflammation but had an inconclusive effect on NT-proBNP, with a trend toward a favorable effect that did not reach statistical significance. No difference in LV infarct size as assessed with CMR was observed compared with placebo. JACC CRT2026.<\/p>\n<hr>\n<p>The Journal of the American College of Cardiology (JACC) stands as a leading global resource for impactful cardiovascular research, delivering essential peer-reviewed articles and crucial clinical practice guidelines. Gain access to authoritative medical content and vital CME resources designed to advance cardiovascular medicine and improve heart patient outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Early IL-6 receptor inhibition with tocilizumab in AMI patients at increased risk of CS safely suppressed systemic inflammation but had an inconclusive effect on NT-proBNP, with a trend toward a favorable effect that did not reach statistical significance. No difference in LV infarct size as assessed with CMR was observed compared with placebo. JACC CRT2026. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-232832","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=232832"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232832\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=232832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=232832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=232832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}